Dispensing of potentially teratogenic drugs before conception and during pregnancy: a population-based study.

Autor: Zomerdijk IM; Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, the Netherlands.; Department of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands.; Dutch Medicines Evaluation Board, Utrecht, the Netherlands., Ruiter R; Department of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands., Houweling LM; PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands., Herings RM; PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands., Straus SM; Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, the Netherlands., Stricker BH; Department of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands.; Drug Safety Unit, Inspectorate of Health Care, The Hague, the Netherlands.
Jazyk: angličtina
Zdroj: BJOG : an international journal of obstetrics and gynaecology [BJOG] 2015 Jul; Vol. 122 (8), pp. 1119-29. Date of Electronic Publication: 2014 Oct 15.
DOI: 10.1111/1471-0528.13128
Abstrakt: Objective: To study the dispensing of potentially teratogenic drugs in the 12-month period before as well as during pregnancy in the Netherlands.
Design: Population-based study.
Setting: A cohort was constructed using a linkage between the PHARMO Database Network and the Netherlands Perinatal Registry (PRN).
Population: A total of 203 962 Dutch pregnancies reported between 1999 and 2007 METHODS: Drug-dispensing information was identified from the PHARMO Database Network for the 12-month period before conception and during pregnancy. Drugs with either a Swedish FASS 'D' classification, an Australian ADEC or American FDA 'D' or 'X' classification were considered potentially teratogenic (n = 202).
Mean Outcome Measures: Proportion of pregnancies that received potentially teratogenic drugs in the 12-month period before and during pregnancy and specific for the risk category X drugs and newly initiated drugs.
Results: Sixteen percent of the pregnancies received a potentially teratogenic drug in the 12-month period before and 5.07% during pregnancy. Doxycycline and paroxetine were most frequently received during pregnancy by 1.01% and 0.85% of women, respectively; 0.66% of the women received a risk category X drug during pregnancy which most frequently consisted of triptorelin (0.25%), norethisterone (0.22%) and simvastatin (0.03%). Fifty-three percent of the women who received a potentially teratogenic drug during pregnancy received this for the first time during the study period. These percentages were heterogeneous between therapeutic drug classes.
Conclusions: Five percent of the pregnancies received a potentially teratogenic drug during pregnancy and 0.66% received a drug from the risk category X. It may be possible to reduce these proportions when reasons for prescription have been explored.
(© 2014 Royal College of Obstetricians and Gynaecologists.)
Databáze: MEDLINE
Externí odkaz: